13F Holdings
中文EN

SNTI Senti Biosciences Holdings, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1854270 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY9.6%
TTM EPS YoY51.2%
Revenue 3-yr CAGR-69.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-67,652.7%
Net margin-58,140.5%
FCF margin—
EBITDA margin-63,736.5%

Returns

ROE—
ROA-106.2%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets133.9%
Debt / equity—
Current ratio0.54x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-19.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$22,000$0$2.56M$4.29M$2.76M
R&D expense$37.59M$34.36M$32.15M$28.14M$21.96M
SG&A expense$26.16M$26.37M$37.18M$38.23M$21.25M
Operating income-$68.78M-$61.04M-$92.73M-$62.08M-$40.45M
Income tax$0$0———
Net income-$61.44M-$52.79M-$71.06M-$58.21M-$55.32M
EBITDA-$65.14M-$57.20M-$89.17M-$60.68M-$39.68M
EPS (basic)-2.73-12.03-16.01-2.23-19.00
EPS (diluted)-2.73-12.03-16.01-2.23-19.00
Weighted avg. shares (diluted)22.48M4.60M4.44M26.11M2.91M
Balance sheet
Cash & equivalents$16.42M$51.81M$39.45M$60.99M$59.29M
Short-term investments——$0$40.94M$0
Receivables———$626,000$483,000
Current assets$23.27M$58.96M$71.20M$102.58M$60.19M
PP&E, net$12.89M$21.29M$25.34M$51.36M$12.37M
Total assets$51.22M$97.84M$119.48M$180.79M$96.70M
Current liabilities$13.97M$13.15M$12.67M$18.05M$14.54M
Total liabilities$45.63M$47.09M$52.57M$53.53M$36.33M
Shareholders' equity$5.59M$25.65M$66.91M$127.26M-$111.46M
Shares outstanding30.88M4.83M4.57M44.06M2.97M
Cash flow statement
Operating cash flow-$43.44M-$41.40M-$52.40M-$34.90M-$34.63M
Capital expenditure$196,000$26,000$12.04M$41.37M$5.54M
Free cash flow-$43.64M-$41.42M-$64.43M-$76.27M-$40.18M
Investing cash flow-$184,000$34,000$30.08M-$81.96M-$5.54M
Financing cash flow$11.76M$53.73M$779,000$118.55M$68.44M
Depreciation & amortization$3.64M$3.84M$3.56M$1.40M$769,000
Stock-based compensation$5.71M$1.75M$9.67M$16.39M$2.29M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.